The use of viral load reduction as a surrogate marker could help expedite changes in monoclonal antibodies aimed at tackling emerging variants of the SARS-CoV-2 virus.
During a 16 February meeting sponsored by the Duke-Margolis Center for Health Policy, former FDA commissioner Scott Gottlieb described policy...